3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
22
Carcinoma, Transitional Cell
20
Ureteral Neoplasms
7
Urologic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Urogenital Neoplasms
2
Urethral Neoplasms
2
Muscle Invasive Bladder Urothelial Carcinoma
2
Metastatic Urothelial Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Advanced Bladder Cancer
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Interventions
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Nivolumab
1
Mitomycin
1
Human Papillomavirus DNA Tests
1
Gemcitabine
1
Fluorouracil
1
Colposcopy
1
Cisplatin
1
Biopsy
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
enfortumab vedotin
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled